Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canacord Genuity bumps up target price on Paragon

(Sharecast News) - Canaccord Genuity raised its target price on specialist finance provider Paragon from 958.0p to 1,001.0p on Thursday following the group's H1 trading results in June. Canaccord Genuity nudged its underlying pre-tax forecasts 0%-2% higher for FY25-27 and upgraded its underlying diluted earnings per share estimates by 2%-3%, accounting for an additional £50.0m share buyback, which Paragon announced alongside its results.

The Canadian bank also noted that a decision from the Supreme Court on "hidden commissions" in motor finance could be imminent, with July being suggested by the Court. In H125, Paragon took a provision of £6.5m related to motor finance commissions liabilities and while Canaccord Genuity noted that it was difficult for it to judge whether this was adequate based on available information, it cautioned that "the first provision is not usually the last".

"However, we note that the provision relative to the size of the motor net loan book appears to be within the peer group range," said Canaccord, which reiterated its 'buy' rating on the stock. "PAG previously disclosed that with respect to 'hidden commissions', which is the subject of the current Supreme Court review, between 2014 to Sep 24 it paid £9.0m of commission to broker-dealers (the subject of the case), just 18% of the total £49.0m motor commissions it paid."

Canaccord said its new target price makes further allowance for potential liability concerning motor finance commissions significantly above the provision already taken, implying 9% upside and a total shareholder return of 14%.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.